Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.
Feature | Peripheral Artery Disease (PAD) | Dave Fornell, Editor

The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003 ...

Home January 25, 2019
Home
News | Stents

The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few years ...

Home January 22, 2019
Home
News | Peripheral Artery Disease (PAD)

January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers ...

Home January 17, 2019
Home
Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018
Feature | Stents Bioresorbable | Dave Fornell, Editor

Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology has ...

Home October 12, 2018
Home
Videos

Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston Scientific ...

Home October 11, 2018
Home
Videos

A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston ...

Home October 11, 2018
Home
News | Stents

October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials ...

Home October 04, 2018
Home
News | Intra-Vascular Ultrasound (IVUS)

October 2, 2018 — Intravascular ultrasound (IVUS) guidance improved clinical outcomes over angiography guidance during d ...

Home October 02, 2018
Home
News | Stents Drug Eluting

October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer ...

Home October 01, 2018
Home
Technology | Stents Drug Eluting

October 1, 2018 — Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its ...

Home October 01, 2018
Home
News | Stents Drug Eluting

September 26, 2018 — Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 ...

Home September 26, 2018
Home
News | Stents Drug Eluting

May 31, 2018 – Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the ...

Home May 31, 2018
Home
News | Stents Drug Eluting

May 31, 2018 — Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking ...

Home May 31, 2018
Home
News | Stents Drug Eluting

May 29, 2018 – Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing ...

Home May 29, 2018
Home
News | Stents Bifurcation

May 29, 2018 – Medtronic plc announced the initiation of a U.S. clinical study to assess the safety and efficacy of drug ...

Home May 29, 2018
Home
Subscribe Now